Pharsight

Recently opposed patents at EPO

These are the recently opposed patents at EPO. This will help you to understand the market dynamics and the potential opportunities.

Patent Number Patent Title Company Recent Opposition Date Recent Opposition By Activity Alert
EP3810201B9 Gip/glp1 agonist compositions NA 23 Feb, 2024
SANDOZ
EP2995315B1 Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction NA 22 Feb, 2024
LEEMING
EP3651730 NEUE ZUSAMMENSETZUNG ZUM GLT- TEN VON HAAREN NEW COMPOSITION FOR STRAIGHTEN- ING HAIR NOUVELLE COMPOSITION POUR LE LIS- SAGE DES CHEVEUX DI VISCO 20 Feb, 2024
HENKEL
EP3666797B1 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) AMGEN INC 19 Feb, 2024
(Expiration: Aug, 2028)
REGENERON PHARMACEUTICALS
(and 1 more)
EP2687202B1 Subcutaneous anti-her2 antibody formulation NA 12 Feb, 2024
ACCORD HEALTHCARE
EP3485890B1 Treatment of metabolic disorders in canine animals NA 09 Feb, 2024
CEVA SANTE ANIMALE
EP2508188B1 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate NA 09 Feb, 2024
GALENICUM HEALTH SLU
(and 4 more)
EP3263110B1 Solid preparation NA 08 Feb, 2024
SANDOZ
EP3250681B1 Compositions and methods for t cell delivery of therapeutic molecules NA 05 Feb, 2024
JAMES POOLE
EP3883606B9 Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody JANSSEN BIOTECH INC 05 Feb, 2024
(Expiration: Sep, 2039)
SAMSUNG BIOEPIS NL
(and 1 more)
EP3613421B1 Dry powder inhaler and methods of use NA 02 Feb, 2024
GENERICS UK
EP3240842B1 Novel film coating composition NA 01 Feb, 2024
KADOR & PARTNER PARTG MBB
EP4093367B1 Isotropic concentrate and wash compositions NA 30 Jan, 2024
HENKEL
EP4090310B1 Hair treatment composition NA 26 Jan, 2024
DALLI WERKE
EP4023755B1 Artificial nucleic acid molecules for improved protein expression CUREVAC SE 26 Jan, 2024
(Expiration: Dec, 2035)
SANOFI
(and 3 more)
EP4021929B1 Ham15-52 analogues with improved amylin receptor (hamy3r) potency NA 26 Jan, 2024
STRAWMAN
EP3525775B1 Arginine and its use as a t cell modulator INSTITUTE FOR RESEARCH IN BIOMEDICINE IRB 25 Jan, 2024
(Expiration: Oct, 2037)
COHAUSZ & FLORACK PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
EP3368047B1 Synthetic composition and method for modulating emotion and mood disorders GLYCOM AS 25 Jan, 2024
(Expiration: Oct, 2036)
WEICKMANN & WEICKMANN PARTMBB
EP3892295B1 Individualized vaccines for cancer TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH 25 Jan, 2024
(Expiration: May, 2032)
WITHERS & ROGERS LLPJONES NICHOLASWRIGHT HOWARD WALLIN NICHOLAS
EP3697392B1 Tablets comprising tamsulosin and solifenacin SYNTHON BV 23 Jan, 2024
(Expiration: Oct, 2038)
ADALVO
EP3363811B1 Method for producing fusion protein having igg fc domain ALTEOGEN INC 18 Jan, 2024
(Expiration: Oct, 2036)
JAMES POOLE
(and 3 more)
EP3769781B1 Stable anti-ifnar1 formulation ASTRAZENECA AB 18 Jan, 2024
(Expiration: Aug, 2036)
MAIWALD
EP3233204B1 Composition for enhancing hair fiber properties PROCTER AND GAMBLE CO 16 Jan, 2024
(Expiration: Dec, 2035)
HENKEL
EP3886820B8 Capsule formulations CHEMOCENTRYX INC 12 Jan, 2024
(Expiration: Nov, 2039)
LEK PHARMACEUTICALS DD
(and 1 more)
EP2858496B9 Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors SOLUTEX NA LLC 11 Jan, 2024
(Expiration: May, 2033)
EPAX NORWAY
EP3970513B1 Non-tobacco oral nicotine pouch composition PHILIP MORRIS PRODUCTS SA 11 Jan, 2024
(Expiration: Nov, 2040)
NICOVENTURES TRADING
EP3648796B1 Dispersion for an aqueous spray formulation with controlled mechanical degradation GREENA BV 05 Jan, 2024
(Expiration: Jul, 2037)
STRAWMAN
EP3930670B1 Bio-based pearlescent waxes BASF SE 04 Jan, 2024
(Expiration: Feb, 2040)
CLARIANT PRODUKTE DEUTSCHLAND
(and 1 more)
EP3618875B1 Combination therapy comprising a raf inhibitor and trametinib NOVARTIS AG 04 Jan, 2024
(Expiration: Apr, 2038)
STADA ARZNEIMITTEL
EP3724319B1 Methods for obtaining muscle derived cells INNOVACELL AG 03 Jan, 2024
(Expiration: Dec, 2038)
OLIGSCHLGER
EP3954690B1 Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide ACERTA PHARMA BV 29 Dec, 2023
(Expiration: Jul, 2036)
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
EP3439647B1 Composition for use in reducing or preventing global developmental delay in children NUTRICIA NV 21 Dec, 2023
(Expiration: Apr, 2036)
SOCIT DES PRODUITS NESTL
EP3416658B1 Human functional corneal endothelial cell and application thereof KYOTO PREFECTURAL PUBLIC UNIV CORP 20 Dec, 2023
(Expiration: Feb, 2037)
VO
EP2658520B1 Leave-in conditioning composition for hair KAO GERMANY GMBH 18 Dec, 2023
(Expiration: Dec, 2031)
HENKEL
EP3512505B1 Vildagliptin pharmaceutical compositions GALENICUM HEALTH SL 15 Dec, 2023
(Expiration: Sep, 2037)
ELKINGTON AND FIFE
(and 1 more)
EP3290043B1 Enzyme-treated milk product, method for producing same, composition, and product SAISEI PHARMA CO LTD 15 Dec, 2023
(Expiration: May, 2036)
NUTRICIA
EP3645553B1 Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells REGENERON PHARMACEUTICALS INC 15 Dec, 2023
(Expiration: Jun, 2038)
STRAWMAN
(and 1 more)
EP3598967B1 Personal cleansing compositions, methods and uses PROCTER AND GAMBLE CO 15 Dec, 2023
(Expiration: Jul, 2038)
UNILEVER UNILEVER
EP3179986B1 Dry powder formulations for inhalation VECTURA INC 14 Dec, 2023
(Expiration: Jul, 2035)
GENERICS UK
EP3727599B8 Composition for dyeing keratin fibers containing a combination of a p-phenylene derivative and 2,7-naphthalenediol and use thereof for reducing a yellow tinge in a hairstyle LABORATOIRE BIOSTHETIQUE KOSMETIK & CO KG GMBH 14 Dec, 2023
(Expiration: Dec, 2037)
HENKEL
EP4070788B1 Pharmaceutical formulations GILEAD SCIENCES INC 11 Dec, 2023
(Expiration: Jun, 2036)
ZENTIVA
EP3294283B1 Sacubitril-valsartan dosage regimen for treating heart failure NOVARTIS AG 08 Dec, 2023
(Expiration: May, 2036)
ZENTIVA
(and 14 more)
EP3042669B1 Antitumor agent and antitumor effect enhancer TAIHO PHARMACEUTICAL CO LTD 07 Dec, 2023
(Expiration: Sep, 2034)
GENERICS UK
(and 1 more)
EP3402573B1 Composition containing amino acids INDIVIDUAL 01 Dec, 2023
(Expiration: Jan, 2037)
ARLA FOODS AMBA
(and 1 more)
EP3000467B1 Treatment regimen utilizing neratinib for breast cancer WYETH LLC 01 Dec, 2023
(Expiration: Mar, 2030)
GENERICS UK
(and 2 more)
EP2981272B1 Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease ZS PHARMA INC 01 Dec, 2023
(Expiration: Apr, 2034)
GENERICS UK
(and 1 more)
EP4066819B1 Small liposomes for delivery of immunogen-encoding rna GLAXOSMITHKLINE BIOLOGICALS SA 01 Dec, 2023
(Expiration: Aug, 2031)
JG OPPOSITIONS
(and 3 more)
EP3686211B1 Process for efficient purification of neutral human milk oligosaccharides (hmos) from microbial fermentation CHR HANSEN HMO GMBH 30 Nov, 2023
(Expiration: Dec, 2034)
GREAVES BREWSTER
(and 1 more)
EP3680249B1 Process for efficient purification of neutral human milk oligosaccharides (hmos) from microbial fermentation CHR HANSEN HMO GMBH 30 Nov, 2023
(Expiration: Dec, 2034)
GREAVES BREWSTER
(and 1 more)
EP4070787B1 Pharmaceutical formulations GILEAD SCIENCES INC 29 Nov, 2023
(Expiration: Jun, 2036)
ZENTIVA
EP3880160B1 Dentifrice containing sodium bicarbonate and stannous ions. COLGATE PALMOLIVE CO 27 Nov, 2023
(Expiration: Dec, 2039)
HALEON UK
EP3302507B1 Diagnostic methods for t cell therapy US DEPARTMENT OF HEALTH AND HUMAN SERVICES 22 Nov, 2023
(Expiration: May, 2036)
BOULT WADE TENNANT
EP3395383B1 Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo REGEN LAB SA 22 Nov, 2023
(Expiration: Aug, 2027)
ESTAR
EP3811943B1 Compound for use in the treatment of ocular disorders AERIE PHARMACEUTICALS INC 22 Nov, 2023
(Expiration: Mar, 2034)
TER MEER STEINMEISTER & PARTNER PATENTANWLTE MBB
(and 2 more)
EP3880197B1 Methods of treatment for cystic fibrosis VERTEX PHARMACEUTICALS INC 22 Nov, 2023
(Expiration: Nov, 2039)
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
EP3393510B1 Zika virus vaccine VALNEVA AUSTRIA GMBH 21 Nov, 2023
(Expiration: Dec, 2036)
MAIWALD
EP3534939B1 Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof BOEHRINGER INGELHEIM VETMEDICA GMBH 21 Nov, 2023
(Expiration: Nov, 2037)
ZOETIS SERVICES
EP2575744B1 Skin treatment composition UNILEVER GLOBAL IP LTD 27 Oct, 2023
(Expiration: May, 2031)
BEIERSDORF
EP4010082B1 Multispecific anti-tcr delta variable 1 antibodies GAMMADELTA THERAPEUTICS LTD 25 Oct, 2023
(Expiration: Aug, 2041)
MARGARET DIXON
EP3551160B1 Flexible solid cosmetic composition comprising sulfonate anionic surfactants, fatty esters and fatty alcohols, and cosmetic treatment method LOREAL SA 23 Oct, 2023
(Expiration: Nov, 2037)
HENKEL
EP3805248B1 Process for concentration of antibodies and therapeutic products thereof NOVARTIS AG 18 Oct, 2023
(Expiration: Sep, 2025)
KILBURN & STRODE
(and 1 more)
EP3122426B1 Treating breast cancer using selective estrogen receptor modulators DUKE UNIVERSITY 18 Oct, 2023
(Expiration: Mar, 2035)
SANDOZ
(and 1 more)
EP3362055B1 Sglt-2 inhibitor for use in the treatment of a metabolic myopathy BOEHRINGER INGELHEIM INTERNATIONAL GMBH 17 Oct, 2023
(Expiration: Oct, 2036)
GENERICS UK
(and 1 more)
EP2482812B1 Pharmaceutical compositions comprising bi-1356 and metformin BOEHRINGER INGELHEIM INTERNATIONAL GMBH 11 Oct, 2023
(Expiration: Oct, 2030)
GALENICUM
(and 2 more)
EP3318259B1 Stable pharmaceutical composition for oral administration ASTELLAS PHARMA INC 11 Oct, 2023
(Expiration: Jul, 2036)
GENERICS UK
(and 1 more)
EP4043040B1 Small liposomes for delivery of immunogen-encoding rna GLAXOSMITHKLINE BIOLOGICALS SA 11 Oct, 2023
(Expiration: Aug, 2031)
JG OPPOSITIONS
(and 3 more)
EP4011915B8 Methods for treating or preventing asthma by administering an il-4r antagonist SANOFI BIOTECHNOLOGY SAS 11 Oct, 2023
(Expiration: Aug, 2033)
LUIGI
EP3264923B1 Compositions for use in the prevention or treatment of gastrointestinal infections in infants or young children SOCIETE DES PRODUITS NESTLE SA 11 Oct, 2023
(Expiration: Mar, 2036)
RECKITT BENCKISER HEALTH
(and 1 more)
EP3897726B1 Dietetic butyrate SOCIETE DES PRODUITS NESTLE SA 04 Oct, 2023
(Expiration: Dec, 2039)
AAK PUBL
EP3937662B1 Non-tobacco oral nicotine pouch composition PHILIP MORRIS PRODUCTS SA 04 Oct, 2023
(Expiration: Nov, 2040)
NICOVENTURES TRADING
EP4019041B1 Toxicity management for anti-tumor activity of cars CHILDRENS HOSPITAL OF PHILADELPHIA CHOP 28 Sep, 2023
(Expiration: Jul, 2033)
GEDEON RICHTER PHARMA
(and 2 more)
EP4008357B1 Small liposomes for delivery of immunogen-encoding rna GLAXOSMITHKLINE BIOLOGICALS SA 28 Sep, 2023
(Expiration: Aug, 2031)
HPFNER
(and 3 more)
EP4066855B1 Pegylated liposomes for delivery of immunogen-encoding rna GLAXOSMITHKLINE BIOLOGICALS SA 28 Sep, 2023
(Expiration: Aug, 2031)
THOMANN
(and 3 more)
EP2968201B1 Enhanced drug delivery from adhesives AVERY DENNISON CORP 27 Sep, 2023
(Expiration: Mar, 2034)
BIOCOM SYSTEMS
EP3464277B1 Pegylated carfilzomib compounds AMGEN INC 27 Sep, 2023
(Expiration: May, 2037)
LUIGI
EP3581650B1 Factor ix polypeptide mutant, its uses and a method for its production UNIQURE BIOPHARMA BV 27 Sep, 2023
(Expiration: Sep, 2029)
PFIZER
EP3285776B1 Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function MELINTA THERAPEUTICS INC 21 Sep, 2023
(Expiration: Apr, 2036)
GENERICS UK
EP2566469B1 Combination therapy BOEHRINGER INGELHEIM INTERNATIONAL GMBH 21 Sep, 2023
(Expiration: May, 2031)
GENERICS UK
(and 1 more)
EP4066857B1 Pegylated liposomes for delivery of immunogen-encoding rna GLAXOSMITHKLINE BIOLOGICALS SA 21 Sep, 2023
(Expiration: Aug, 2031)
THOMANN
(and 3 more)
EP3883603B1 Igm protease antigen vaccine for protecting against streptococcus suis INTERVET INTERNATIONAL BV 19 Sep, 2023
(Expiration: Nov, 2039)
CEVA SANTE ANIMALE
EP3318281B1 Highly purified sugars and sugar compositions CORIOLIS PHARMA RESEARCH GMBH 15 Sep, 2023
(Expiration: Nov, 2036)
GRNECKER PATENT UND RECHTSANWLTE PARTG MBB
EP3634468B1 Solid compositions for oral administration NOVO NORDISK AS 14 Sep, 2023
(Expiration: Jun, 2038)
GENERICS UK
EP3886795B1 Composition for keratin fibers comprising a direct dye LOREAL SA 14 Sep, 2023
(Expiration: Nov, 2039)
HENKEL
EP3517539B1 Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes BOEHRINGER INGELHEIM INTERNATIONAL GMBH 14 Sep, 2023
(Expiration: Jul, 2032)
KNPP PARTGMBB
(and 2 more)
EP3119423B1 Treatment of cancer using chimeric antigen receptor NOVARTIS AG 14 Sep, 2023
(Expiration: Mar, 2035)
PATENT BOUTIQUE
(and 2 more)
EP3138415B1 Metabolic imprinting effects of specifically designed lipid component NUTRICIA NV 14 Sep, 2023
(Expiration: Jun, 2032)
SOCIT DES PRODUITS NESTL
EP3445407B1 Compositions and methods of cellular immunotherapy CRAGE MEDICAL CO LTD 13 Sep, 2023
(Expiration: Apr, 2037)
MURGITROYD
(and 1 more)
EP3471766B1 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens INTERVET INTERNATIONAL BV 12 Sep, 2023
(Expiration: Jun, 2037)
BOEHRINGER INGELHEIM VETMEDICA
EP3694607B1 Compact shampoo composition PROCTER AND GAMBLE CO 12 Sep, 2023
(Expiration: Oct, 2038)
HENKEL
EP3738585B1 Direct compression formulation and process NOVARTIS AG 11 Sep, 2023
(Expiration: Jan, 2025)
HERZOG PATENTANWALTS
EP3532016B1 Method of preparing a product composition comprising a discrete particle and an aqueous base composition PROCTER AND GAMBLE CO 07 Sep, 2023
(Expiration: Apr, 2038)
HENKEL
EP3877395B1 Industrial process for the preparation of high purity estetrol RICHTER GEDEON NYRT 07 Sep, 2023
(Expiration: Sep, 2040)
INDUSTRIALE CHIMICA
EP3752510B1 Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them VERTEX PHARMACEUTICALS INC 07 Sep, 2023
(Expiration: Feb, 2039)
TEVA PHARMACEUTICAL INDUSTRIES
EP4066856B1 Pegylated liposomes for delivery of immunogen-encoding rna GLAXOSMITHKLINE BIOLOGICALS SA 07 Sep, 2023
(Expiration: Aug, 2031)
WEICKMANN & WEICKMANN PARTMBB
(and 3 more)
EP3355919B1 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers JULIUS MAXIMILIANS UNIVERSITAET WUERZBURG 06 Sep, 2023
(Expiration: Sep, 2036)
PFIZER
EP3578175B1 Rapid dissolution formulation of a calcium receptor-active compound AMGEN INC 30 Aug, 2023
(Expiration: Sep, 2024)
BIOGARAN
(and 6 more)
EP3067043B1 Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor NOVARTIS AG 30 Aug, 2023
(Expiration: Nov, 2028)
GENERICS UK
(and 5 more)
EP2635537B1 Lithium silicate glasses or glass ceramics, method for production thereof and use thereof FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV 30 Aug, 2023
(Expiration: Jun, 2031)
IVOCLAR VIVADENT
EP3516966B1 A concentrated krill protein hydrolysate fraction RIMFROST TECHNOLOGIES AS 29 Aug, 2023
(Expiration: Sep, 2029)
AKER BIOMARINE ANTARCTIC
EP3920970B1 Method for treating checkpoint inhibitors induced adverse events ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP 23 Aug, 2023
(Expiration: Feb, 2040)
JG OPPOSITIONS